Loading...

CSL Limited

CMXHFPNK
HealthcareBiotechnology
$152.16
$-13.64(-8.23%)

CSL Limited (CMXHF) Stock Overview

Explore CSL Limited’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-24.99%
24.99%
Profit Growth
$5.68
20.81%
EPS Growth
$5.68
20.95%
Operating Margin
21.23%
57.73%
ROE
15.30%
20.81%
Dividend Yield
0.00%
21.65%
Analyst Recommendations data is not available for CMXHFAnalyst Recommendations details for CMXHF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

CEO

Dr. Paul F. McKenzie Ph.D.

Employees

32,698

Headquarters

45 Poplar Road, Melbourne, VIC

Founded

2005

Frequently Asked Questions